Literature DB >> 18477712

Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease.

L Costelloe1, A Thompson, C Walsh, N Tubridy, M Hutchinson.   

Abstract

OBJECTIVES: To determine the long-term outcome of a cohort of 436 patients with multiple sclerosis (MS) seen in 1985 and long-term predictors of benign MS.
METHODS: The initial 1985 group of 436 patients with possible MS, including 53 benign patients, were followed for 21 years. Disability was recorded using the Expanded Disability Status Scale (EDSS). Survival from disease onset was calculated. The indicators of benign MS in the initial 1985 cohort and in the survivors in 2006 were determined.
RESULTS: Of the original 436 patients, the 21-year follow-up outcome in 397 (91%) was established. The diagnosis of MS was incorrect in 41/397 (10%) of the whole cohort and in 2/53 (4%) of the benign group. Median survival of 356 patients with MS was 43.6 years from disease onset. Of 47/51 (92%) patients with benign MS followed in 2006, 7 (15%) remained benign, 18 had died and 22 were disabled. Median survival advantage for the 47 benign patients in 1985 compared to the 88 non-benign patients, when corrected for age, was 6 years (p<0.08). In 2006, 40/356 (11%) patients had a benign outcome at a mean follow-up of 26.1 years. A benign course was significantly associated with female sex, younger age of onset and absence of motor symptoms at presentation.
CONCLUSIONS: Although designating patients as having a benign course after 10 years has a poor predictive value, three factors at presentation indicate a better prognosis.

Entities:  

Mesh:

Year:  2008        PMID: 18477712     DOI: 10.1136/jnnp.2008.143586

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

Review 1.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

2.  Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.

Authors:  Arianna Sartori; Mohammad Abdoli; Mark S Freedman
Journal:  J Neurol       Date:  2017-04-17       Impact factor: 4.849

3.  Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.

Authors:  Kristin M Galetta; Jennifer Graves; Lauren S Talman; Deacon J Lile; Elliot M Frohman; Peter A Calabresi; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2012-06       Impact factor: 3.042

4.  Quantitative T2' imaging in patients with clinically isolated syndrome.

Authors:  L Y Reitz; M Inglese; J Fiehler; J Finsterbusch; B Holst; C Heesen; R Martin; S Schippling
Journal:  Acta Neurol Scand       Date:  2012-01-03       Impact factor: 3.209

5.  Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.

Authors:  D J Rigotti; A Gass; L Achtnichts; M Inglese; J S Babb; Y Naegelin; J Hirsch; M Amann; L Kappos; O Gonen
Journal:  Mult Scler       Date:  2011-09-15       Impact factor: 6.312

6.  Global N-acetylaspartate declines even in benign multiple sclerosis.

Authors:  D J Rigotti; O Gonen; R I Grossman; J S Babb; A Falini; B Benedetti; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-21       Impact factor: 3.825

7.  Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis.

Authors:  D J Rigotti; M Inglese; I I Kirov; E Gorynski; N N Perry; J S Babb; J Herbert; R I Grossman; O Gonen
Journal:  Neurology       Date:  2012-04-18       Impact factor: 9.910

8.  Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.

Authors:  Lutz Achtnichts; Oded Gonen; Daniel J Rigotti; James S Babb; Yvonne Naegelin; Iris-Katharina Penner; Kerstin Bendfeldt; Jochen Hirsch; Michael Amann; Ludwig Kappos; Achim Gass
Journal:  Eur J Radiol       Date:  2013-09-04       Impact factor: 3.528

9.  Disability in multiple sclerosis: a reference for patients and clinicians.

Authors:  Ilya Kister; Eric Chamot; Amber R Salter; Gary R Cutter; Tamar E Bacon; Joseph Herbert
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

Review 10.  Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.

Authors:  Alberto Gajofatto; Massimiliano Calabrese; Maria Donata Benedetti; Salvatore Monaco
Journal:  Dis Markers       Date:  2013-11-10       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.